Navigation Links
Thoratec Announces Appointment of Paul LaViolette to Board of Directors
Date:5/15/2009

PLEASANTON, Calif., May 15 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced the election of Paul A. LaViolette, the former chief operating officer of Boston Scientific, to its board of directors. LaViolette was elected by the company's shareholders at the company's annual shareholders' meeting on May 13 and brings the number of the company's directors to eight.

LaViolette spent 14 years at Boston Scientific and served as chief operating officer from 2004-2008. Before that, he was senior vice president and group president for several of the company's divisions and its international operations. He was formerly associated with C.R. Bard, Inc., where he held senior management positions and led several of the company's divisions.

"We are pleased to have someone with Paul's broad cardiovascular and medical device experience joining our board. His industry knowledge and successful track record of growing medical technology businesses will be of great value to Thoratec as we pursue our growth strategies," said Gary F. Burbach, president and chief executive officer of Thoratec.

"I also want to acknowledge the contributions of those directors who are stepping down. Dr. J. Donald Hill, a founder of the company and a director since its inception, is a pioneer in the development and use of ventricular assist devices and played a major role at Thoratec throughout the history of the company. Howard Chase, who served as a director for more than 20 years, provided great counsel and support as the company became a leader in treating advanced stage heart failure," Burbach added.

Thoratec Corporation is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System), with more than 13,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at http://www.thoratec.com or http://www.itcmed.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. ITC, A-VOX Systems AVOXimeter, HEMOCHRON, ProTime and IRMA are registered trademarks of International Technidyne Corporation. CentriMag is a registered trademark of Levitronix, LLC.

Many of the preceding paragraphs, particularly but not exclusively those addressing future performance, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products, the results of enrollment in and timing of clinical trials, including the HeartMate II, the effects of FDA regulatory requirements and the effects of healthcare reimbursement and coverage policies. Forward-looking statements contained in this press release should be considered in light of these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading "Risk Factors" in Thoratec's most recent annual report on Form 10-K and as may be updated in subsequent SEC filings. These forward-looking statements speak only as the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thoratec Schedules Third Quarter Conference Call, Webcast
2. Thoratecs ITC Division Receives FDA Warning Letter
3. URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
4. Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
5. Thoratec Schedules First Quarter 2008 Conference Call, Webcast
6. Thoratec Schedules Second Quarter 2008 Conference Call, Webcast
7. Thoratec Reports 44 Percent Increase in Second Quarter Revenues;
8. Thoratec Presentation at Piper Jaffary Conference to be Webcast
9. Thoratec Schedules Fiscal 2008 Year-End Conference Call, Webcast
10. Thoratec Reports 34 Percent Increase in 2008 Revenues
11. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology: